Literature DB >> 26766392

Selective decontamination of the digestive tract and oropharynx: after 30 years of debate is the definitive answer in sight?

Richard J Price1, Brian H Cuthbertson.   

Abstract

PURPOSE OF REVIEW: Selective digestive or oropharyngeal decontamination has been being used as a means to prevent infections and death in intensive care patients for the past 30 years. It remains controversial and its use is limited. In this review, we summarize the recently published data on efficacy of selective decontamination and effects on antibiotic resistances. RECENT
FINDINGS: The most recent meta-analysis shows a reduced mortality when selective digestive or oropharyngeal decontamination are compared with either standard care or oropharyngeal chlorhexidine. Selective decontamination is associated with reduced bacteraemia, and although this effect is greater with selective digestive decontamination compared with selective oropharyngeal decontamination, there is not a mortality difference between these two interventions. Reanalysis of infection data suggests, however, that selective decontamination may also have effects on concurrent control groups. Current evidence generally shows that antibiotic resistance is decreased although much of these data come from the Netherlands (an area with low endemic antibiotic resistance rates). There are currently two huge cluster randomized clinical trials, one in early recruitment, one in development, which will hopefully provide definitive answers in the years to come.
SUMMARY: Current evidence suggests that selective decontamination reduces mortality without increasing antibiotic resistances; this will be tested again in two huge international trials.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26766392     DOI: 10.1097/MCC.0000000000000281

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  5 in total

1.  Prolonged antibiotic prophylaxis after thoracoabdominal esophagectomy does not reduce the risk of pneumonia in the first 30 days: a retrospective before-and-after analysis.

Authors:  Marcel Hochreiter; Maria Uhling; Leila Sisic; Thomas Bruckner; Alexandra Heininger; Andreas Hohn; Katja Ott; Thomas Schmidt; Marc Moritz Berger; Daniel Christoph Richter; Markus Büchler; Markus Alexander Weigand; Cornelius Johannes Busch
Journal:  Infection       Date:  2018-06-05       Impact factor: 3.553

2.  Antipathy against SDD is justified: We are not sure.

Authors:  Michael Quintel; Francesco Vasques; Luciano Gattinoni
Journal:  Intensive Care Med       Date:  2018-06-07       Impact factor: 17.440

3.  De Novo Synthesis of Phosphorylated Triblock Copolymers with Pathogen Virulence-Suppressing Properties That Prevent Infection-Related Mortality.

Authors:  Jun Mao; Alexander Zaborin; Valeriy Poroyko; David Goldfeld; Nathaniel A Lynd; Wei Chen; Matthew V Tirrell; Olga Zaborina; John C Alverdy
Journal:  ACS Biomater Sci Eng       Date:  2017-07-17

4.  Protocol for a multi-centered, stepped wedge, cluster randomized controlled trial of the de-adoption of oral chlorhexidine prophylaxis and implementation of an oral care bundle for mechanically ventilated critically ill patients: the CHORAL study.

Authors:  Craig M Dale; Louise Rose; Sarah Carbone; Orla M Smith; Lisa Burry; Eddy Fan; Andre Carlos Kajdacsy-Balla Amaral; Victoria A McCredie; Ruxandra Pinto; Carlos R Quiñonez; Susan Sutherland; Damon C Scales; Brian H Cuthbertson
Journal:  Trials       Date:  2019-10-24       Impact factor: 2.279

5.  Use of selective gut decontamination in critically ill children: protocol for the Paediatric Intensive Care and Infection Control (PICnIC) pilot study.

Authors:  Alanna Brown; Paloma Ferrando; Mariana Popa; Gema Milla de la Fuente; John Pappachan; Brian Cuthbertson; Laura Drikite; Richard Feltbower; Theodore Gouliouris; Isobel Sale; Robert Shulman; Lyvonne N Tume; John Myburgh; Kerry Woolfall; David A Harrison; Paul R Mouncey; Kathryn M Rowan; Nazima Pathan
Journal:  BMJ Open       Date:  2022-03-11       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.